Rebuttal to Deacon and Holst: “Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1” versus “Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”

By Demuth H-U.   Hinke S.A.   Pederson R.A.   McIntosh C.H.S.  

Biochemical and Biophysical Research Communications, Vol. 296, Iss. 2, 2002-08 ,pp. : 229-232

Elsevier

Access to resources Recommend Favorite

Treatment of diabetes with glucagon-like peptide-1 gene therapy

By Riedel Michael J   Kieffer Timothy J  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 12, 2010-12 ,pp. : 1681-1692

Informa Healthcare

Access to resources Recommend Favorite

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

By Yasuda N.   Inoue T.   Nagakura T.   Yamazaki K.   Kira K.   Saeki T.   Tanaka I.  

Biochemical and Biophysical Research Communications, Vol. 298, Iss. 5, 2002-11 ,pp. : 779-784

Elsevier

Access to resources Recommend Favorite

Glucagon-like Peptide 1 Increases Glucose-Dependent Activity of the Homeoprotein IDX-1 Transactivating Domain in Pancreatic β-Cells

By Hussain M.A.   Habener J.F.  

Biochemical and Biophysical Research Communications, Vol. 274, Iss. 3, 2000-08 ,pp. : 616-619

Elsevier

Access to resources Recommend Favorite

Point Mutations in the First and Third Intracellular Loops of the Glucagon-like Peptide-1 Receptor Alter Intracellular Signaling

By Heller R.S.   Kieffer T.J.   Habener J.F.  

Biochemical and Biophysical Research Communications, Vol. 223, Iss. 3, 1996-06 ,pp. : 624-632

Elsevier

Access to resources Recommend Favorite